Go back to /resources
Back
Position Statements
Canadian Position Statement on Opioid Therapy
November 23, 2017
Pain is a prevalent and often severe symptom that impacts global health status for almost every patient with a rheumatic disease. In response to the Guideline for opioid therapy and chronic non-cancer pain published in the Canadian Medical Association Journal...
Related Resources
View All
Position Statements
Canadian Rheumatology Association Position Statement on Criteria for Access to Targeted Agents for Rheumatoid Arthritis in Canada
There are currently significant discrepancies between Canadian provinces and territories in the criteria for access to advanced targeted agents for rheumatoid arthritis (RA) treatment. Such targeted agents include biologic medications as well as small molecule inhibitors. In hopes of supporting […]
March 30, 2026
Position Statements
Canadian Rheumatology Association Position Statement for Vaccinations in Patients with Rheumatic Diseases
This new position statement replaces the Canadian Rheumatology Association Position Statement on COVID-19 Vaccination (latest update published March 2022), and advocates for government coverage for vaccines not currently funded for rheumatology patients.
February 18, 2026
Position Statements
Canadian Rheumatology Association Position Statement on Hydroxychloroquine Monitoring Guidance for Optical Coherence Tomography
The antimalarial drugs, hydroxychloroquine (HCQ) and rarely chloroquine, are essential drugs in the treatment of rheumatic diseases. HCQ is currently the only anti-malarial drug available in Canada for the treatment of rheumatic diseases...
December 1, 2025